Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

Clinical Cancer Research, 05/15/2012

Ruxolitinib offers a well–tolerated oral therapeutic option for patients with myelofibrosis with symptomatic splenomegaly and debilitating disease–related symptoms, but it does not seem to be effective at eliminating the underlying hematological malignancy.

Print Article Summary Cat 2 CME Report